DMD and Duchenne muscular dystrophy: In a cohort study carried out over 6 months with 12 DMD patients that had point mutations in different exons, six patients saw an increase in their levels of dystrophin after the treatment with six patients reaching real increased levels (post-treatment minus pre-treatment level of dystrophin) of 10.4, 10.9, and 11% respectively for point mutations in exons 25, 33, and 35 (18).